Skip to main content
Premium Trial:

Request an Annual Quote

Roche NimbleGen SeqCap EZ MedExome Target Enrichment Kit

Roche NimbleGen has globally launched the SeqCap EZ MedExome target enrichment kit, a comprehensive whole-exome sequencing solution designed to increase the discovery and detection of human genetic variants associated with disease while reducing sequencing costs. The design targets the genome assembly GRCh38/hg38 (coordinates for hg19 annotation are also available) with comprehensive sequencing coverage of medically relevant and protein-coding regions. The product has been extensively optimized in design, empirical rebalancing, and manufacturing to increase coverage in hard-to-sequence regions for a more uniform and complete exome, Roche NimbleGen noted. SeqCap EZ MedExome produces greater than 85 percent on-target rate, and demonstrates high uniformity across the targeted region with about 98 percent sensitivity for SNP detection and greater than 99 percent specificity for SNP allele classification, according to Roche.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.